At Ashion®, we provide industry-leading next-generation clinical decision support approaches that leverage the genetic information from a patient’s tumor and normal genomes. Our clinical genomics testing laboratory offers unparalleled genomic data analysis and interpretation approaches to assist clinicians and patients in navigating the field of precision medicine.

GEM Cancer Panel™

The GEM Cancer Panel™ uncovers true tumor-specific (somatic) alterations.

The GEM (Genomic-Enabled Medicine) Cancer Panel™ is Ashion Analytics™ flagship clinical assay. In a single test, the GEM Cancer Panel™ determines damage to any one of hundreds of genes known to be cancer causing or cancer-related. The strategy of the GEM Cancer Panel™ is to uncover true tumor-specific (somatic) alterations by comparing the sequence of the tumor against the paired normal (germline) DNA from each patient.

 

Each tumor’s cancer-specific alterations are then queried against a proprietary knowledge base to identify potential therapeutic associations. The final report provides the physician with a list of FDA-approved agents that are associated with tumor-specific DNA alteration(s) as well as biomarker summaries on the variant(s) found, and tumor-specific evidence for drug matches, including matches with investigational agents as available on clinicaltrials.gov.
Features:
  • Sequences the coding region of 562 genes
  • High sensitivity for detecting point mutations
  • Target enrichment followed by sequencing on a HighSeq 2500 (Illumina, Inc.)
  • Quick turnaround time: 10-14 days
  • Tumor-specific variations identified with >99% accuracy when using both tumor and normal DNA
  • Germline subtraction decreases false-positive rate

Specimen types:

  • FFPE or fresh frozen tumor
  • Peripheral blood
GEM GW™ Exome Sequencing

GEM GW™ (Genome Wide) sequencing utilizes NGS to selectively sequence a patient's exome.

GEM GW™ (Genome Wide) sequencing utilizes Next-Generation Sequencing (NGS) as an efficient strategy to selectively sequence a patient’s exome. GEM GW™ employs the same tumor-normal approach of the GEM Cancer Panel™ and includes copy number and structural events. A technical report with run quality metrics is provided along with sequence data in the form of Variant Call Files (VCF). GEM GW™ is currently offered to research/academic groups involved in clinical trials.
Features:
  • Currently offered to research/academic groups involved in clinical trials
  • Can be selected independently or ordered in tandem with RNA Seq to confirm presence of therapeutically actionable target(s)
  • Technical report with run quality metrics provided along with sequence data in the form of VCFs

Specimen types:

  • Fresh Frozen Tissue
  • Peripheral blood
RNA Sequencing

RNA Sequencing increases the likelihood of a therapeutic response.

RNA sequencing (RNA Seq) uses the capabilities of Next-Generation Sequencing (NGS) to reveal a snapshot of RNA presence and quantity from a genome at a given moment in time, providing the ability to look at alternative gene spliced transcripts, post-transcriptional changes, gene fusion, mutations such as single nucleotide polymorphisms (SNPs) and changes in gene expression. RNA Seq can
be used to identify and then prioritize identified targets based on whether or not they are expressed in the transcriptome, thus increasing the likelihood of a therapeutic response.

Features:

  • Currently offered to research/academic groups involved in clinical trials
  • Can be selected independently or ordered to complement the results of a GEM Cancer Panel™ or GEM GW™ test to confirm presence of therapeutically actionable target(s)
  • Technical report with run quality metrics provided along with sequence data in the form of VCFs.

Specimen Types:

  • Fresh Frozen Tissue

Learn how Next-Generation Sequencing can impact your practice today.